

(51) International Patent Classification:
C07D 413/06 (2006.01)(21) International Application Number:
PCT/US2012/059983(22) International Filing Date:
12 October 2012 (12.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/547,637 14 October 2011 (14.10.2011) US
61/638,990 26 April 2012 (26.04.2012) US(71) Applicant: **AMBIT BIOSCIENCES CORPORATION**
[US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA
92121 (US).(72) Inventors: **HADD, Michael J.**; 4510 Brighton Avenue,
San Diego, CA 92107 (US). **HOCKER, Michael D.**; 7528
Flanders Drive, San Diego, CA 92126 (US). **HOL-
LADAY, Mark W.**; 4215 Sorrento Valley Boulevard, San
Diego, CA 92121 (US). **LIU, Gang**; 4215 Sorrento Valley
Boulevard, San Diego, CA 92121 (US). **ROWBOTTOM,
Martin W.**; 4215 Sorrento Valley Boulevard, San Diego,CA 92121 (US). **XU, Shimin**; 16660 Honeybrook Avenue,
San Diego, CA 92121 (US).(74) Agents: **INSOGNA, Anthony M.** et al.; Jones Day, 222
East 41st Street, New York, NY 10017-6702 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF


(57) Abstract: Provided herein are heterocyclic compounds
for treatment of CSFIR, FLT3, KIT, and/or PDGFR β kinase
mediated diseases. Also provided are pharmaceutical compos-
itions comprising the compounds and methods of using the
compounds and compositions.

FIG. 1



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, **Published:**
ML, MR, NE, SN, TD, TG).

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*